Ashley Marie Dickey, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 505 E Matthews Ave Ste 303, Jonesboro, AR 72401 Phone: 870-932-4211 |
Mark D Adkins, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 909 Enterprise Dr, Jonesboro, AR 72401 Phone: 870-336-1100 |
Scott Saunders, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 225 E Jackson Ave, Jonesboro, AR 72401 Phone: 870-932-4211 Fax: 870-931-9141 |
Mrs. Fairyn Marissa Wester, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 505 E Matthews Ave Ste 303, Jonesboro, AR 72401 Phone: 870-932-4211 |
John Mark Rutter, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 225 E Jackson Ave, Jonesboro, AR 72401 Phone: 870-207-4100 |
Mr. Jacob Rathbun, Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 225 E Washington Ave, Jonesboro, AR 72401 Phone: 870-207-4100 |
Kymberly Myers, CRNA Nurse Anesthetist, Certified Registered Medicare: Accepting Medicare Assignments Practice Location: 225 E Jackson Ave, Jonesboro, AR 72401 Phone: 870-932-4211 Fax: 870-931-9141 |
News Archive
Epilepsy is a wide-spread neurological disorder that affects around 50 million people worldwide. It is characterized by recurrent epileptic seizures, which are sudden bursts of electrical activity in the brain.
Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient).
Shire plc, the global specialty biopharmaceutical company, announces that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the U.S. District Court for the District of Delaware against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals, Inc. for the infringement of U.S. Patent No. 6,773,720.
Ampio Pharmaceuticals, Inc. today announced an update on the phase III, multicenter, double-blind STEP study of Ampion™ for osteoarthritis of the knee.
For the first time, scientists from the Florida campus of The Scripps Research Institute have identified small molecules that allow for complete control over a genetic defect responsible for the most common adult onset form of muscular dystrophy.
› Verified 3 days ago